Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

3d illustration of cells secreting exosomes

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the launch of a collaboration focused on rare diseases with the University of Oxford’s Oxford-Harrington Rare Disease Centre embedded within the Department of Paediatrics. The collaboration will run over three years and will capitalise on the world-class exosome research environment in Oxford, leveraging exosome therapeutics expertise and resources from both Evox and the University to drive innovation within rare disease drug development.

The Oxford-Harrington Rare Disease Centre – an affiliation between the University of Oxford and Harrington Discovery Institute – is a global leader in cutting-edge rare disease translational research. Through this collaboration, the parties will stimulate and support innovative approaches to identify and develop exosome therapeutics for the treatment of rare diseases. The collaboration also acts as a platform for the acceleration of translational exosome therapeutics research projects and seeks to build a strong cohort of scientists with in-depth knowledge of the exosome drug discovery process from both the academic and industrial perspective.

We are very pleased to be collaborating with a world-class institute like the Oxford-Harrington Rare Disease Centre on exosomes and their application to the treatment of life-threatening rare diseases. In bringing together our expertise, we can maximise the potential of our exciting technology to bring more options to patients struggling with rare diseases. - Dr Antonin de Fougerolles, Chief Executive Officer of Evox

Exosome therapeutics have the potential to significantly alter the landscape of rare disease treatment for the better. We are delighted to have entered into this collaboration with Evox, a leader in the field, to explore this area. We will look to leverage our joint resources and scientific expertise to identify exciting new treatment options. - Professor Georg Holländer, Head of Department, Department of Paediatrics

Similar stories

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

New Research Highlights Importance of Early Years Development on Future Wellbeing

Oxford researchers involved nearly 4,000 children across the UK in three specially developed science lessons to educate pupils about brain development during early childhood. The SEEN (Secondary Education around Early Neurodevelopment) project was commissioned and funded by KindredSquared and is part of a wider drive to increase public understanding of how early experiences can shape the adults we become.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.